{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:02:57Z","timestamp":1784538177935,"version":"3.55.0"},"reference-count":119,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The alarming increase in the number of new bacterial defense mechanisms is exacerbating the problem of antibiotic resistance and poses a serious obstacle to the treatment of bacterial infections. Despite the approval of numerous new antibiotics by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), mainly from the beta-lactam group since 2000, only some of them possess unique mechanisms of action and activity against multidrug-resistant Gram-negative bacilli (MDR GNB), including carbapenem resistance. Eravacycline (EVT), formerly known as TP-434, is a newly developed non-beta-lactam, fully synthetic tetracycline derivative, approved for the treatment of complicated intra-abdominal infections (cIAIs) in adults. Results: The analysis demonstrated significant efficacy of EVT across a wide range of in vitro and in vivo studies against MDR GNB, including carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) and Gram-positive vancomycine-resistant pathogens. Conclusions: The broad spectrum of activity and favorable safety profile of EVT are well-documented in the treatment of critically ill patients. However, its efficacy against clinically relevant Gram-negative bacteria varies depending on specific species and resistance phenotypes, particularly among carbapenem-resistant and extensively drug-resistant (XDR) isolates.<\/jats:p>","DOI":"10.3390\/jcm15145617","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:54:13Z","timestamp":1784534053000},"page":"5617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4777-4024","authenticated-orcid":false,"given":"Aleksandra","family":"Z\u0142otowska","sequence":"first","affiliation":[{"name":"Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1709-3236","authenticated-orcid":false,"given":"Julia","family":"Kacer","sequence":"additional","affiliation":[{"name":"Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Dybko","sequence":"additional","affiliation":[{"name":"Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7806-3940","authenticated-orcid":false,"given":"Mateusz","family":"Dudek","sequence":"additional","affiliation":[{"name":"Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-4904","authenticated-orcid":false,"given":"Wies\u0142awa","family":"Duszy\u0144ska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","first-page":"e46013","article-title":"Antibiotic Resistance: Challenges and Strategies in Combating Infections","volume":"15","author":"Chavada","year":"2023","journal-title":"Cureus"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Walsh, T.R., Gales, A.C., Laxminarayan, R., and Dodd, P.C. (2023). Antimicrobial Resistance: Addressing a Global Threat to Humanity. PLoS Med., 20.","DOI":"10.1371\/journal.pmed.1004264"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"de Kraker, M.E.A., Stewardson, A.J., and Harbarth, S. (2016). Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002184"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Marino, A., Augello, E., Bellanca, C.M., Cosentino, F., Stracquadanio, S., La Via, L., Maniaci, A., Spampinato, S., Fadda, P., and Cantarella, G. (2025). Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146905"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.3346\/jkms.2020.35.e303","article-title":"Positivity of Carbapenemase-Producing Enterobacteriaceae in Patients Following Exposure within Long-Term Care Facilities in Seoul, Korea","volume":"35","author":"Park","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103227","DOI":"10.1016\/j.iccn.2022.103227","article-title":"Healthcare-Associated Infections in Adult Intensive Care Unit Patients: Changes in Epidemiology, Diagnosis, Prevention and Contributions of New Technologies","volume":"70","author":"Blot","year":"2022","journal-title":"Intensive Crit. Care Nurs."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hetta, H.F., Khalaf, F.R., Kotb, A.A., Alatawi, M.N., Albalawi, A.S., Alharbi, A.A., Aljohani, M.K., Aljohani, S.S., Alatawi, M.S., and Abd Ellah, N.H. (2025). Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens. Pathogens, 15.","DOI":"10.3390\/pathogens15010028"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A Prioritisation Study to Guide Research, Development, and Public Health Strategies against Antimicrobial Resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","first-page":"277","article-title":"The Antibiotic Resistance Crisis: Part 1: Causes and Threats","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tahmasebi, H., Arjmand, N., Monemi, M., Babaeizad, A., Alibabaei, F., Alibabaei, N., Bahar, A., Oksenych, V., and Eslami, M. (2025). From Cure to Crisis: Understanding the Evolution of Antibiotic-Resistant Bacteria in Human Microbiota. Biomolecules, 15.","DOI":"10.3390\/biom15010093"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1264\/jsme2.ME3002rh","article-title":"Survivability of Microbes in Natural Environments and Their Ecological Impacts","volume":"30","author":"Haruta","year":"2015","journal-title":"Microbes Environ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e24655","DOI":"10.1002\/jcla.24655","article-title":"Antibiotic Resistance: The Challenges and Some Emerging Strategies for Tackling a Global Menace","volume":"36","author":"Ugwu","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Salam, M.A., Al-Amin, M.Y., Salam, M.T., Pawar, J.S., Akhter, N., Rabaan, A.A., and Alqumber, M.A.A. (2023). Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare, 11.","DOI":"10.20944\/preprints202305.0555.v1"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Machado, E., and Sousa, J.C. (2025). New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria. Antibiotics, 14.","DOI":"10.3390\/antibiotics14100997"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s44259-025-00123-1","article-title":"Current Economic and Regulatory Challenges in Developing Antibiotics for Gram-Negative Bacteria","volume":"3","author":"Gargate","year":"2025","journal-title":"npj Antimicrob. Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s44307-025-00059-7","article-title":"An Alternative Approach to Combat Multidrug-Resistant Bacteria: New Insights into Traditional Chinese Medicine Monomers Combined with Antibiotics","volume":"3","author":"Dai","year":"2025","journal-title":"Adv. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e14510","DOI":"10.1111\/1751-7915.14510","article-title":"The Antibiotic Resistance Crisis and the Development of New Antibiotics","volume":"17","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a Newly Approved Fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_19","unstructured":"(2026, June 04). Xerava (Eravacycline): EPAR Product Information. European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xerava-epar-product-information_en.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rusu, A., and Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122085"},{"key":"ref_22","first-page":"583973","article-title":"Comparative in Vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae","volume":"19","author":"Chen","year":"2026","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Falagas, M.E., Romanos, L.T., Kontogiannis, D.S., Filippou, C., and Karageorgopoulos, D.E. (2025). Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies. Pathogens, 14.","DOI":"10.3390\/pathogens14121214"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A Review in Complicated Intra-Abdominal Infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","article-title":"Eravacycline: A Comprehensive Review of in Vitro Activity, Clinical Efficacy, and Real-World Applications","volume":"22","author":"Huang","year":"2024","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ataman, M., and \u00c7elik, B.\u00d6. (2025). Investigation of the in Vitro Antimicrobial Activity of Eravacycline Alone and in Combination with Various Antibiotics against MDR Acinetobacter baumanni Strains. BMC Microbiol., 25.","DOI":"10.1186\/s12866-025-03914-8"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The Glycylcyclines: A Comparative Review with the Tetracyclines","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.37201\/req\/141.2025","article-title":"Eravacycline: From Broad-Spectrum Coverage to Novel Clinical Applications","volume":"39","author":"Verdejo","year":"2026","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_31","first-page":"1059","article-title":"Tigecycline in the Treatment of Complicated Intra-Abdominal and Complicated Skin and Skin Structure Infections","volume":"3","author":"Townsend","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/jac\/dkm058","article-title":"AdeABC Multidrug Efflux Pump Is Associated with Decreased Susceptibility to Tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii Complex","volume":"59","author":"Ruzin","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01810","DOI":"10.1128\/AAC.01810-18","article-title":"Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects","volume":"63","author":"Newman","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e01174-18","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0025-7125(16)30039-6","article-title":"Tetracyclines","volume":"79","author":"Klein","year":"1995","journal-title":"Med. Clin. N. Am."},{"key":"ref_36","unstructured":"Shutter, M.C., and Akhondi, H. (2025). Tetracycline, StatPearls Publishing."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","article-title":"Tigecycline (Tygacil): The First in the Glycylcycline Class of Antibiotics","volume":"19","author":"Greer","year":"2006","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jitkova, Y., Gronda, M., Hurren, R., Wang, X., Goard, C.A., Jhas, B., and Schimmer, A.D. (2014). A Novel Formulation of Tigecycline Has Enhanced Stability and Sustained Antibacterial and Antileukemic Activity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095281"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: Nonantibiotic Properties and Their Clinical Implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline Antibacterial Activity, Clinical Effectiveness, and Mechanisms and Epidemiology of Resistance: Narrative Review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Leroux, P., Bornet, C., Bolla, J.-M., and Cohen, A. (2025). Challenges of Carbapenem-Resistant Enterobacteriaceae in the Development of New \u03b2-Lactamase Inhibitors and Antibiotics. Antibiotics, 14.","DOI":"10.3390\/antibiotics14060587"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14787210.2024.2397663","article-title":"Efficacy and Safety of Eravacycline (ERV) in Treating Infections Caused by Gram-Negative Pathogens: A Systematic Review and Meta-Analysis","volume":"22","author":"Chen","year":"2024","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e0139022","DOI":"10.1128\/spectrum.01390-22","article-title":"Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies","volume":"10","author":"Xu","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e0106524","DOI":"10.1128\/aac.01065-24","article-title":"Population Pharmacokinetics and Pulmonary Modeling of Eravacycline and the Determination of Microbiological Breakpoint and Cutoff of PK\/PD","volume":"69","author":"Ji","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12941-025-00847-y","article-title":"Transient AdeABC-Mediated Eravacycline Resistance in Carbapenem-Resistant Acinetobacter baumannii ST2: A Mutation-Independent Efflux Pump Adaptation","volume":"25","author":"Yang","year":"2026","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"117666","DOI":"10.1016\/j.biopha.2024.117666","article-title":"Activity and Resistance Mechanisms of the Third Generation Tetracyclines Tigecycline, Eravacycline and Omadacycline against Nationwide Spanish Collections of Carbapenemase-Producing Enterobacterales and Acinetobacter baumannii","volume":"181","author":"Muras","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e01699\u201319","DOI":"10.1128\/AAC.01699-19","article-title":"In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.2147\/IDR.S425061","article-title":"In Vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives against Levofloxacin-Non-Susceptible And\/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas Maltophilia","volume":"16","author":"Wu","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/jac\/dkae220","article-title":"Establishment of Epidemiological Cut-off Values for Eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus","volume":"79","author":"Jing","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e0171522","DOI":"10.1128\/spectrum.01715-22","article-title":"Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019","volume":"10","author":"Ding","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liao, X., Liang, Q., Dai, X., Wu, S., Duan, C., Luo, Z., and Xie, X. (2024). In Vitro Activities of Eravacycline against Clinical Bacterial Isolates: A Multicenter Study in Guangdong, China. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1504013"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/dkaa386","article-title":"Eravacycline, a Novel Tetracycline Derivative, Does Not Induce Clostridioides Difficile Infection in an in Vitro Human Gut Model","volume":"76","author":"Buckley","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hu, S., Jiang, L., Xu, H., Meng, X., Zhang, D., Zhou, D., Xiao, Y., and Zheng, B. (J. Adv. Res., 2025). Eravacycline and Omadacycline Rescue Multidrug-Resistant Elizabethkingia anophelis: Triple-Model Evaluation across in Vitro, Galleria Mellonella, and Murine Bacteremia Systems, J. Adv. Res., in press.","DOI":"10.1016\/j.jare.2025.11.048"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","first-page":"1","article-title":"Jian Overexpression of OqxAB and MacAB Efflux Pumps Contributes to Eravacycline Resistance and Heteroresistance in Clinical Isolates of Klebsiella pneumoniae","volume":"7","author":"Zheng","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/cid\/ciz1231","article-title":"Safety of Antimicrobials during Pregnancy: A Systematic Review of Antimicrobials Considered for Treatment and Postexposure Prophylaxis of Plague","volume":"70","author":"Yu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2445055","DOI":"10.1001\/jamanetworkopen.2024.45055","article-title":"First Trimester Tetracycline Exposure and Risk of Major Congenital Malformations","volume":"7","author":"Nakitanda","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.70010","article-title":"A Review of Antibiotic Safety in Pregnancy-2025 Update","volume":"45","author":"Nguyen","year":"2025","journal-title":"Pharmacotherapy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline","volume":"58","author":"McCarthy","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00275-18","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits","volume":"62","author":"Petraitis","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/ofid\/ofx163.1359","article-title":"Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects","volume":"4","author":"Horn","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"107186","DOI":"10.1016\/j.ijantimicag.2024.107186","article-title":"Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli: A Practical Approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases","volume":"64","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_66","first-page":"163","article-title":"Programas de Optimizaci\u00f3n Del Uso de Antimicrobianos En Los Servicios de Urgencias Espa\u00f1oles: Estudio PROA-URG [Antibiotic Stewardship Programs in the Spanish Emergency Services: PROA-URG Study]","volume":"37","author":"Grande","year":"2024","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_69","unstructured":"(2026, June 26). Evidence Summary Antimicrobial Prescribing: Eravacycline for Complicated Intra-Abdominal Infections in Adults. Available online: https:\/\/www.nice.org.uk\/advice\/es40\/resources\/antimicrobial-prescribing-eravacycline-for-complicated-intraabdominal-infections-in-adults-pdf-1158290022085."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eimc.2022.06.004","article-title":"Executive Summary of the Consensus Document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the Diagnosis and Antimicrobial Treatment of Infections due to Carbapenem-Resistant Gram-Negative Bacteria","volume":"41","author":"Pintado","year":"2023","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_71","unstructured":"(2026, June 26). Pa\u0142eczki Enterobacterales Wytwarzaj\u0105ce Karbapenemazy (CPE) [Carbapenemase-Producing Enterobacterales (CPE)], Available online: https:\/\/korld.nil.gov.pl\/wp-content\/uploads\/2023\/03\/Rekomendacje-Paleczki-Enterobacterales_2023.21.02-1.pdf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"104589","DOI":"10.1016\/j.bjid.2025.104589","article-title":"Guideline for Antimicrobial Treatment of Multidrug-Resistant Gram-Negative Infections: Practice Recommendations of the Brazilian Society of Infectious Diseases","volume":"29","author":"Zavascki","year":"2025","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","article-title":"Recommendations and Guidelines for the Treatment of Infections due to Multidrug Resistant Organisms","volume":"55","author":"Sy","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13017-024-00551-w","article-title":"Management of Intra-Abdominal Infections: Recommendations by the Italian Council for the Optimization of Antimicrobial Use","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J. Emerg. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jgar.2025.06.021","article-title":"Comparative in Vitro Activities of Eravacycline and Tigecycline against Carbapenem-Resistant Acinetobacter baumannii: Insights from Whole Genome Sequencing Analysis","volume":"44","author":"Zhong","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e0248225","DOI":"10.1128\/spectrum.02482-25","article-title":"Evaluating Eravacycline\u2019s Efficacy against Pediatric Carbapenem-Resistant Klebsiella pneumoniae in China: A 6-Year Study","volume":"14","author":"Zhou","year":"2026","journal-title":"Microbiol. Spectr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e00797-20","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jiph.2024.03.027","article-title":"Evaluation of the Synergistic Effect of Eravacycline and Tigecycline against Carbapenemase-Producing Carbapenem-Resistant Klebsiella pneumoniae","volume":"17","author":"Huang","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"S\u0142abisz, N., Le\u015bnik, P., Janc, J., Fidut, M., Bartoszewicz, M., Dudek-Wicher, R., and Nawrot, U. (2024). Evaluation of the in Vitro Susceptibility of Clinical Isolates of NDM-Producing Klebsiella pneumoniae to New Antibiotics Included in a Treatment Regimen for Infections. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1331628"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-Abdominal Infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Li, Y., Yi, Q., Zhou, M., Lu, M., and Xu, Y. (2026). Real-World Effectiveness and Predictors of Treatment Failure for Eravacycline in Patients with Acinetobacter baumannii or Klebsiella pneumoniae Infections: A Multicenter Retrospective Analysis. Front. Cell. Infect. Microbiol., 16.","DOI":"10.3389\/fcimb.2026.1746200"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.2147\/IDR.S529016","article-title":"Eravacycline Treatment for Carbapenem-Resistant Acinetobacter baumannii in Lung Transplant Recipients: A Real-World Retrospective Study","volume":"18","author":"Chen","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Van Helden, S.R., Coyne, A.J.K., Alosaimy, S., Molina, K.C., Kang-Birken, S.L., Andrade, J., King, M.A., Claeys, K.C., Hobbs, A.L.V., and Perkins, N.B. (2025). Clinical Efficacy and Safety of Eravacycline for the Treatment of Enterococcal Infections: A Subpopulation Analysis. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-11982-4"},{"key":"ref_85","first-page":"276","article-title":"Stenotrophomonas Maltophilia Infections: Could Eravacycline Be a New Weapon for Clinicians?","volume":"48","author":"Giuliano","year":"2025","journal-title":"New Microbiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jgar.2025.09.011","article-title":"The Efficacy and Safety of Eravacycline in the Treatment of Patients with Pneumonia in Respiratory Departments: A Real-World Multicenter Retrospective Study","volume":"45","author":"Luo","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/IDR.S515207","article-title":"Efficacy and Safety of Eravacycline Combination Therapy for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in ICU Patients: A Retrospective Study","volume":"18","author":"Guo","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A Retrospective, Multicentre Evaluation of Eravacycline Utilisation in Community and Academic Hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline","volume":"9","author":"Petrak","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early Experience with Eravacycline for Complicated Infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e0131425","DOI":"10.1128\/spectrum.01314-25","article-title":"Combating Resistant Pathogens: Exploring the Efficacy of Eravacycline Utilization in Multidrug-Resistant Infections","volume":"13","author":"Patino","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_92","first-page":"137","article-title":"Eravacycline: Data Based on Real Evidence","volume":"48","author":"Giuliano","year":"2025","journal-title":"New Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e0235123","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the First Four Years: Health Outcomes and Tolerability Data for 19 Hospitals in 5 U.S. Regions from 2018 to 2022","volume":"12","author":"Alosaimy","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0128725","DOI":"10.1128\/aac.01287-25","article-title":"Clinical Outcomes and Safety of Eravacycline in Hematology: A Multicenter, Real-World Study","volume":"70","author":"Wang","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Oberreiter, K., Moser, M.M., Schneider, L., Burgmann, H., Moreal, C., Giuliano, S., Angelini, J., Tascini, C., and Vossen, M.G. (2026). Real-World Experience on the Use of Eravacycline at Doses of 1 Mg\/kg Bodyweight and Fixed Dose Strategy in Two European Tertiary Centers. Antibiotics, 15.","DOI":"10.3390\/antibiotics15040421"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"McCourt, N.M., Krsak, M., Brade, K., and Casias, M. (2026). Real-World Safety and Efficacy Data Comparing Dosing Strategies of Eravacycline: A Retrospective Cohort Study. Hosp. Pharm., 00185787261417158.","DOI":"10.1177\/00185787261417158"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S651","DOI":"10.1093\/ofid\/ofaa439.1454","article-title":"1270. Early Real-World Evidence in the Use of Eravacycline for the Management of Draconian Infections","volume":"7","author":"Carr","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-Establishing the Utility of Tetracycline-Class Antibiotics for Current Challenges with Antibiotic Resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e0323822","DOI":"10.1128\/spectrum.03238-22","article-title":"In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Si, Y., Chen, M., Zhang, J., Jiang, J., Zhang, Y., Yu, G., Guo, N., Yan, G., and Leng, B. (2026). Incidence and Characteristics of Eravacycline-Associated Increase in Serum Bilirubin Levels: A Retrospective Study. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1585390"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/aid2.13216","article-title":"Eravacycline for the Treatment of Complicated Intra-abdominal Infections","volume":"8","author":"Wang","year":"2021","journal-title":"Adv. Dig. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e0343225","DOI":"10.1128\/spectrum.03432-25","article-title":"Eravacycline Pharmacokinetics\/pharmacodynamics in the Hollow Fiber System Model of Mycobacterium Abscessus Lung Disease","volume":"14","author":"Singh","year":"2026","journal-title":"Microbiol. Spectr."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jpids\/piz085","article-title":"Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children","volume":"9","author":"Chiotos","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"dkaf347","DOI":"10.1093\/jac\/dkaf347","article-title":"Efficacy of Eravacycline in Difficult-to-Treat (DTR) Acinetobacter baumannii Bacteraemia in ICU: A Case Report","volume":"81","author":"Melchio","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijantimicag.2018.01.001","article-title":"Assessment of in Vivo Efficacy of Eravacycline against Enterobacteriaceae Exhibiting Various Resistance Mechanisms: A Dose-Ranging Study and Pharmacokinetic\/pharmacodynamic Analysis","volume":"51","author":"Thabit","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_106","first-page":"e47494","article-title":"Antimicrobial Susceptibility Trends of Proteeae Isolates from a Tertiary-Care Hospital in Western Saudi Arabia","volume":"15","author":"Alotaibi","year":"2023","journal-title":"Cureus"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e0053325","DOI":"10.1128\/aac.00533-25","article-title":"Broad Spectrum of \u03b2-Lactamase Coverage and Potent Antimicrobial Activity of Xeruborbactam in Combination with Meropenem against Carbapenemase-Producing Enterobacterales, Including Strains Resistant to New \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations","volume":"69","author":"Recacha","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wen, Z., Shang, Y., Xu, G., Pu, Z., Lin, Z., Bai, B., Chen, Z., Zheng, J., Deng, Q., and Yu, Z. (2020). Mechanism of Eravacycline Resistance in Clinical Enterococcus Faecalis Isolates from China. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00916"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Li, Y.-T., Chen, X.-D., Guo, Y.-Y., Lin, S.-W., Wang, M.-Z., Xu, J.-B., Wang, X.-H., He, G.-H., Tan, X.-X., and Zhuo, C. (2024). Emergence of Eravacycline Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii Isolates in China. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1356353"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1128\/AAC.05946-11","article-title":"Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium Bovis BCG","volume":"56","author":"Mick","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, Y., Lin, Y., Guo, Y., He, G., Wang, X., Wang, M., Xu, J., Song, M., and Tan, X. (2024). Comparison of Antimicrobial Activities and Resistance Mechanisms of Eravacycline and Tigecycline against Clinical Acinetobacter baumannii Isolates in China. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1417237"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Sun, J.-R., Perng, C.-L., Chan, M.-C., Morita, Y., Lin, J.-C., Su, C.-M., Wang, W.-Y., Chang, T.-Y., and Chiueh, T.-S. (2012). A Truncated AdeS Kinase Protein Generated by ISAba1 Insertion Correlates with Tigecycline Resistance in Acinetobacter baumannii. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049534"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Marino, A., Augello, E., Stracquadanio, S., Bellanca, C.M., Cosentino, F., Spampinato, S., Cantarella, G., Bernardini, R., Stefani, S., and Cacopardo, B. (2024). Unveiling the Secrets of Acinetobacter Baumannii: Resistance, Current Treatments, and Future Innovations. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25136814"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/jac\/dky083","article-title":"Diversity of Mutations in Regulatory Genes of Resistance-Nodulation-Cell Division Efflux Pumps in Association with Tigecycline Resistance in Acinetobacter baumannii","volume":"73","author":"Gerson","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Zhang, F., Bai, B., Xu, G.-J., Lin, Z.-W., Li, G.-Q., Chen, Z., Cheng, H., Sun, X., Wang, H.-Y., and Chen, Y.-W. (2018). Eravacycline Activity against Clinical S. Aureus Isolates from China: In Vitro Activity, MLST Profiles and Heteroresistance. BMC Microbiol., 18.","DOI":"10.1186\/s12866-018-1349-7"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Wang, Z., Lin, Z., Bai, B., Xu, G., Li, P., Yu, Z., Deng, Q., Shang, Y., and Zheng, J. (2020). Eravacycline Susceptibility Was Impacted by Genetic Mutation of 30S Ribosome Subunits, and Branched-Chain Amino Acid Transport System II Carrier Protein, Na\/Pi Cotransporter Family Protein in Staphylococcus aureus. BMC Microbiol., 20.","DOI":"10.1186\/s12866-020-01869-6"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e0256424","DOI":"10.1128\/spectrum.02564-24","article-title":"Antibacterial Activity of Eravacycline against Klebsiella pneumoniae Isolates: An in Vitro Study","volume":"13","author":"Gong","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41429-022-00546-2","article-title":"In Vitro Activity and Adaptation Strategies of Eravacycline in Clinical Enterococcus faecium Isolates from China","volume":"75","author":"Wen","year":"2022","journal-title":"J. Antibiot."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"107624","DOI":"10.1016\/j.ijantimicag.2025.107624","article-title":"Resistance of Gram-Negative Bacteria to Aztreonam-Avibactam: An Evaluation of Data from In Vitro Studies","volume":"66","author":"Falagas","year":"2025","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:10:43Z","timestamp":1784535043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":119,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145617"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145617","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}